Healthcare stocks lift European markets higher; Novo Nordisk jumps 3.4%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2025
0mins
Source: CNBC
European Market Performance: European stocks saw a slight increase, with the Stoxx 600 index up by 0.3%, driven by corporate earnings and positive developments in Germany's federal election where the CDU/CSU alliance gained the most votes.
Corporate Earnings Highlights: Notable gains were reported from companies like Novo Nordisk and Smith & Nephew, while VTB Bank announced a significant profit rise, reflecting a recovery after previous losses due to sanctions.
Analyst Views on SNN
Wall Street analysts forecast SNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNN is 35.75 USD with a low forecast of 34.00 USD and a high forecast of 37.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 33.080
Low
34.00
Averages
35.75
High
37.50
Current: 33.080
Low
34.00
Averages
35.75
High
37.50
About SNN
Smith & Nephew plc is a portfolio medical technology company. The Company is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, which includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilize severe fractures and correct bone deformities; Sports Medicine & ENT businesses offer advanced products and instruments used to repair or remove soft tissue, and Advanced Wound Management provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds. The Company also owns Integrity Orthopaedics, which is an early stage commercial developer of Tendon Seam, an innovative and disruptive biomechanical RCR system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
